Læknablaðið - 15.12.1995, Síða 49

LÆKNABLAÐIÐ 1995; 81
877
primary Sjögren’s syndrome in comparison
with healthy controls and patients with other
rheumatic diseases. In: Homma M, et al, eds.
Sjögren’s syndrome — State of the art. Am-
sterdam/New York: Kugler Publications, 1994:
325-8.
* Björn Guðbjörnsson, Karlsson-Parra A,
Eyþór Karlsson, Hallgren R, Kampe O. Post-
partum thyroiditis and Sjögren’s syndrome. In:
Homma M, et al, eds. Sjögren’s syndrome —
State of the art. Amsterdam/New York: Ku-
gler Publications, 1994: 423-6.
* Arvidson NG, Björn Guðbjörnsson, Elf-
man L, Rydén AC, Tötterman TH, Hallgren
R. Circadian thythm of serum interleukin-6 in
rheumatoid arthritis. Ann Rheum Dis 1994;
53: 521-4.
* Björn Guðbjörnsson, Hallgren R, Nettel-
blad O, Gustafsson R, Mattsson A, Gejerstam
E, Tötterman TH. Phenotypic and functional
activation of alveolar macrophages, T lympho-
cyte and NK cells in patients with systemic
sclerosis and primary Sjögren’s syndrome.
Ann Rheum Dis 1994; 53: 574-9.
* Axel Sigurðsson, Swedberg K, Ullman B.
Effects of ramipril on the neurohormonal re-
sponse to exercise in patients with mild or
moderate congestive heart failure. Eur Heart J
1994; 15: 247-54.
* Axel Sigurðsson, Amtorp O, Gundersen
T, Nilsson B, Remes J, Swedberg K. For The
Ramipril Trial Study Group. Neurohormonal
activation in patients with mild or moderately
severe congestive heart failure and the effects
of ramipril. Br Heart J 1994; 72: 422-7.
* Axel Sigurðsson, Swedberg K. Left ven-
tricular remodelling, neurohormonal activa-
tion and early treatment with enalapril (CON-
SENSUS II) following myocardial infarction.
Eur Heart J 1994; 15/Suppl. B: 14-9.
* Axel Sigurðsson, Swedberg K. Is neuro-
hormonal activation a major determinant of
the response to ACE inhibition in left ventric-
ular dysfunction and heart failure. Br Heart J
1994; 72/Suppl.: 75-80.
* Axel Sigurðsson. Neurohormonal activa-
tion in patients with acute myocardial infarc-
tion or chronic congestive heart failure — with
special reference to treatment with angiotensin
converting enzyme inhibitors. Blood Pressure
1995; Suppl. I: 1—45.
* Axel Sigurðsson, Swedberg K. ACE in-
hibitors in patients with minimally or asympto-
matic left ventricular dysfunction. Cor Art Dis
1995; 6: 288-94.
* Axel Sigurðsson, Swedberg K. Pharmac-
ological treatment of chronic heart failure (edi-
torial). Cardiology 1995; 1: 35—46.
* Axel Sigurðsson, Swedberg K. Pharmac-
ological treatment of chronic heart failure.
L’Information Cardiologique, 1995.
* Ullman B, Lindvall K, Lundberg JM, Ax-
el Sigurðsson, Swedberg K. Response of plas-
ma neuropeptide Y and noradrenaline to dy-
namic exercise and ramipril treatment in pa-
tients with congestive heart failure. Clin
Physiol 1994; 14: 123-34.
* Axel Sigurðsson, Swedberg K. Patient
management after acute myocardial infarc-
tion. Cardiotopics 1994; 13-8.
* Axel Sigurðsson, Swedberg K. Conges-
tive Heart Failure. In: Conn’s Current ther-
apy. Philadelphia: WB Saunders, 1995: 252-7.
* Axel Sigurðsson. The role of the sympa-
thetic and renin-angiotensin system in conges-
tive heart failure. Invited lecture, plenary ses-
sion: new aspects of chronic heart failure.
XVth Nordic Congress of Cardiology June 7-9
1995, Malmö, Sweden.
* Andersson G, Alfvegren E, Eneroth P,
Axel Sigurðsson. Does the use of a torniquet
affect plasma concentration of neurohormones
in patients with myocardial infarction? XVth
Nordic Congress of Cardiology June 7-9 1995,
Malmö, Sweden.
* Ólafur Baldursson, Kristján Steinsson,
Jóhannes Björnsson, Lie JT. Giant Cell Arter-
itis in Iceland. An Epidemiologic and Histo-
pathologic Analysis. Arthritis Rheum 1994;
37: 1007-12.
* Árni Jón Geirsson, Kristján Steinsson,
Sveinn Guðmundsson, Vigfús Sigurðsson. Sys-
temic Sclerosis in Iceland. A nationwide epide-
miological study. Ann Rheum Dis 1994; 53:
502-5.
* Kristján Steinsson, Kristján Erlendsson.
Bindvávssjukdomar av blandform (DCTD) —
en översikt. Nord Med 1994; 109: 231-5.